SynAct Pharma Q3 loss after tax narrows 10% to SEK 32.18 million

Bitget2026/11/03 06:33

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

SynAct Pharma’s third-quarter 2026 loss after tax narrowed 10% year over year to SEK 32.18 million.
Operating expenses fell 15% to SEK 30.09 million compared with the year-earlier quarter.
Quarter-end cash and cash equivalents dropped 46% year over year to SEK 42.36 million.
On October 27, SynAct signed its first commercial partnership for resomelagon with a leading Brazilian pharmaceutical company.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SynAct Pharma AB published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Jensen Huang has been the key driving force behind the massive expansion of AI infrastructure, with his personal credibility and authoritative decision-making deeply embedded in the narrative of the global tech market’s rise over the past three years. Now, as scandals emerge, Nvidia’s trading team is expected to become more conservative and slow down external financing commitments, which undoubtedly worsens the situation for neoclouds already facing tight funding.

华尔街见闻•2026/11/09 09:21